Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials
Explore this paper's citation graph
Summary
It is suggested that durable control of the hematologic disease is most critical to improve overall outcome of patients with increased comorbidity, and fludarabine plus cyclophosphamide compared to chlorambucil treatment.
- Type
- article
- Published
- 2014-02-28
- Cited by
- 111
- References
- 25
- Access
- Open access
- OpenAlex
- https://openalex.org/W2098983980
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:20516378
Keywords
Fludarabine, Chronic lymphocytic leukemia, Comorbidity, Medicine, Chlorambucil
References
- National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
- Prognostic importance of comorbidity in a hospital-based cancer registry.
- Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia
- A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
- Validation of the Cumulative Illness Rating Scale in a Geriatric Residential Population
- Update on therapy of chronic lymphocytic leukemia.
- State of the art treatment of chronic lymphocytic leukaemia.
- First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
- A population‐based study of severity of comorbidity among patients with non‐Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index
- Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
- Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer.
- Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia
- Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
- A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia
- Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
- Differential prognostic impact of comorbidity.
- Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans.
Cited by
- Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial
- Integrating Oncogeriatric Tools into the Management of Chronic Lymphocytic Leukemia: Current State of the Art and Challenges for the Future
- Chronische lymphatische Leukämie beim alten Patienten
- Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
- Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015
- Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope
- Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study
- Chronic Lymphocytic Leukemia: Diagnosis and Treatment
- Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
- Management of chronic lymphocytic leukemia in elderly patients
- Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia
- Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model
- New meets old: a case study and review of novel therapeutics for the treatment of CLL in older patients.
- How I treat chronic lymphocytic leukemia in older patients.
- Towards improved frontline treatment of CLL in the elderly.
- Reappraising prognosis in chronic lymphocytic leukemia
- Integration of Chinese Herbal Medicine Therapy Improves Survival of Patients With Chronic Lymphocytic Leukemia
- Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies
- The beneficial local and abscopal effect of splenic irradiation in frail patients with chronic lymphocytic leukaemia.
Related papers
- Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
- Chlorambucil and fludarabine as a new pre-transplant conditioning for patients with chronic lymphocytic leukemia: results of in vivo experiments
- Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
- Fludarabine versus chlorambucil: is the debate over?
- Treatment algorithms in CLL
- The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial.
- First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.